Oragenics Reports $2.2 Million Net Loss in Q1 2025, Sees Increase in Total Assets

Oragenics, Inc. reported its financial results for the first quarter of 2025, revealing a net loss of $2.2 million, a decrease from the $2.45 million loss recorded in the same period of 2024. The company did not generate any revenue during this quarter, consistent with its performance in the previous year. Total operating expenses for the quarter were $2.03 million, down from $2.46 million in the prior year, primarily due to a significant reduction in research and development costs, which fell by 48.5% to $341,542. General and administrative expenses also decreased by 6.2% to $1.68 million.

In terms of financial position, Oragenics reported total assets of $3.87 million as of March 31, 2025, a substantial increase from $1.47 million at the end of 2024. This growth was largely attributed to a significant rise in cash and cash equivalents, which increased to $3.42 million from $864,840. The company’s liabilities also rose, with total liabilities reaching $3.73 million, up from $1.68 million, primarily due to the issuance of a $3 million promissory note. Shareholders' equity improved to $137,688, compared to a deficit of $211,885 at the end of the previous fiscal year.

Strategically, Oragenics has been active in financing its operations, raising $2.6 million through the sale of 7.8 million shares of common stock in February 2025. Additionally, the company issued a $3 million promissory note in March 2025, which is intended to support working capital and general corporate purposes. The company also designated 1,000,000 shares of preferred stock as Series G Mirroring preferred stock in connection with this note. These actions reflect Oragenics' ongoing efforts to secure funding for its product development initiatives, particularly for its lead candidate, ONP-002, aimed at treating mild traumatic brain injury.

Operationally, Oragenics continues to focus on the development of its nasal delivery pharmaceutical products, particularly ONP-002. The company has completed pre-clinical animal studies and is preparing for future clinical trials. However, the company has acknowledged that it will require additional financing to continue its operations beyond the third quarter of 2025. The management has expressed concerns regarding its ability to sustain operations without further capital, given its accumulated deficit of $219 million and ongoing losses.

Looking ahead, Oragenics anticipates that its general and administrative expenses will increase as it expands its research and development activities and seeks additional capital. The company is actively exploring strategic partnerships and financing options to support its long-term goals. However, it remains uncertain whether it will be able to secure the necessary funding on favorable terms, which could impact its ability to advance its product candidates and achieve profitability in the future.